To Assess the Bioavailability of TK-254RX in Comparison with Oral Flurbiprofen Tablets and the Adhesion of TK-254RX in Healthy Subjects

Inclusion Criteria: * age: 18 years to 64 years (inclusive) * body-mass index (BMI): ≥18.5 kg/m² and ≤ 30.0 kg/m² * good state of health * non-smoker or ex-smoker for at least 3 months * written informed consent, after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the subjects participating in the clinical triall Exclusion Criteria: * existing cardiac and/or haematological diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient * existing or history of hypertension and/or heart failure * existing hepatic and/or renal diseases or pathological findings, which might interfere with the safety or tolerability, and/or pharmacokinetics of the active ingredient * existing gastrointestinal diseases or pathological findings, which might interfere with the safety, tolerability, absorption and/or pharmacokinetics of the active ingredient * history of gastrointestinal bleeding or perforation related to previous NSAID therapy * active, or history of ulcerative colitis, Crohn's disease, peptic ulceration or gastrointestinal haemorrhage * existing metabolic, endocrine and/or immunologic diseases or pathological findings, which might interfere with the safety or tolerability, and/or pharmacokinetics of the active ingredient * diabetes mellitus * hyperlipidaemia (LDL \> 4.16 mmol/l, HDL \< 0.91 mmol/l, triglycerides \> 2.28 mmol/l, cholesterol \> …